Passage Bio (NASDAQ:PASG – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $7.

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio (PASG – Research Report) yesterday and set a price target ...

Passage Bio, Inc. ( (PASG)) has released its Q3 earnings. Here is a breakdown of the information Passage Bio, Inc. presented to its investors. Passage Bio, Inc. is a clinical-stage genetic medicines ...

PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, ...

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases ...

Featured here, the Income Statement (earnings report) for Passage Bio Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and ...

Opus Genetics Inc (IRD) is expected to report $-0.33 for 3Q. Passage Bio Inc (PASG) is expected to report $-0.23 for 3Q. Pieris Pharmaceuticals Inc (PIRS) is expected to report for 3Q. Reliv ...

The 15th Dakar Biennale, ‘The Wake,’ takes place in the Ancien Palais de Justice near the western-most point of the continent ...

Don’t pet the fluffy cows. That’s the Instagram bio tagline for the National Park Service’s popular account, which showcases ...

One of the reasons I selected King from the 855 women who served in the five units of the 6888th Central Postal Directory Battalion is because she, at one time, was considered one of the last ...